Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS

Engel P, Wu JJ. Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS. Exp Dermatol. 2025 Aug;34(8):e70146. doi: 10.1111/exd.70146. PMID:[...]

Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

Novel Virtual Reality Intervention for Stress Reduction Among Patients With or at Risk for Cardiovascular Disease: Mixed Methods Pilot Study

Makaroff KE, Van C, Grospe V, Edmunds L, Calfon-Press MA, Watson KE, Horwich T. Novel Virtual Reality Intervention for Stress Reduction Among Patients With or[...]